S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY

• L. Vinti,
• S. Daw,
• C. Sabado Alvarez,
• F. Fagioli,
• A. Beishuizen,
• G. Michel,
• M. L. Moleti,
• M. Cepelova,
• A. Thorwarth,
• C. Rigaud,
• D. Plaza Lopez de Sabando,
• J. Landman Parker,
• Y. Zhu,
• P. Pillai,
• A. Nahar,
• C. Mauz-Koerholz

Affiliations

L. Vinti

1 IRCCS Ospedale Pediatrico Bambino, Gesu, Italy

S. Daw

2 University College London Hospitals NHS Foundation Trust, London, United Kingdom

C. Sabado Alvarez

3 Hospital Universitari Vall d Hebron, Barcelona, Spain

F. Fagioli

4 Ospedale Infantile Regina Margherita, Turin, Italy

A. Beishuizen

5 Princess Máxima Centrum, Utrecht, Netherlands

G. Michel

6 CHU de Marseille Hopital de la Timone Enfants, Marseille, France

M. L. Moleti

7 Universita degli Studi di Roma La Sapienza, Rome, Italy

M. Cepelova

8 Fakultni nemocnice v Motole, Prague, Czechia

A. Thorwarth

9 Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum, Berlin, Germany

C. Rigaud

10 Gustave Roussy Cancer Campus, Villejuif, France

D. Plaza Lopez de Sabando

11 Hospital Universitario La Paz, Madrid, Spain

J. Landman Parker

12 Hopital d’Enfants Armand Trousseau, Paris, France

Y. Zhu

13 Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, United States of America

P. Pillai

13 Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, United States of America

A. Nahar

13 Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, United States of America

C. Mauz-Koerholz

14 Justus-Liebig University of Giessen, Giessen